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Review
Ecstasy abuse: an Irish perspective
The last two decades have seen a transformation in the
way young people socialise. In addition to tobacco and
alcohol, an increasing number of young people take
recreational drugs including ecstasy (3, 4-
methylenedioxymethamphetamine [MDMA]) as part of their
night out. A key factor in the increasing use of recreational
drugs is their association with nightclubs, dance music and
‘raves’. The popularity of ecstasy is due to its positive effects
on mood and feeling of well-being, and the fact that most
young people perceive it to be a safe drug.
However, there have been a substantial number of reports
of severe acute toxicity and death.1 The rate of ecstasy use by
teenagers in Ireland is amongst the highest in Europe
(ESPAD, 1999) with 1 in 20 16 year olds reported to have
taken ecstasy.2 Although less prevalent than cannabis, ecstasy
and amphetamines are the second most commonly used
drugs in the general population.
In the latter half of the 1990s, there was a decreasing trend
in those presenting to treatment services with problematic
ecstasy use, from 7.4% in 1995 to 3.5% in 1998. This trend did
not continue however, and there was an increase in the
proportion of people to 5.9% in 2000 presenting with ecstasy
problems.3 After cannabis, ecstasy is the drug that features
next in prosecutions and drug seizures data in Ireland.
Ecstasy seizures come mostly from street or dance events,
rather than from point of entry to the country. The number of
seizures recorded by Gardai increased quite considerably
from 534 in 1996 to 1,910 in 2000.3
History
Ecstasy was first synthesised and patented in Germany by
Merck in 1914. The intention was to market it as an appetite
suppressant, but the drug was never released onto the
market for this indication. However, there are published
reports of the use of MDMA as an adjunct to psychotherapy,
as it was said to enhance the ‘therapeutic alliance by inviting
self-disclosure and promoting trust’.4 Since the mid-1980s,
ecstasy had become popular as a recreational drug and, by
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1987, deaths involving MDMA use were being described.
(There are now a substantial number of reports in the
literature implicating MDMA with severe acute toxicity
problems or death.1)
At the same time, reports were beginning to appear that the
drug and its demethylated metabolite, 3,4-
methylenedioxyamphetamine (MDA) had long-term
neurotoxic effects on laboratory animals.5 These reports have
done little to prevent the widespread use of ecstasy as one of
the most popular illicit recreational drugs.
In 1985, the US Drug Enforcement Administration restricted
the therapeutic use of MDMA, placing it on Schedule 1 of its
Restricted Drugs List. It is classified similarly in Ireland
(Schedule 1 of the Misuse of Drugs Act, 1977) and the UK
(Class A under the Misuse of Drugs Act).
Abuse patterns
Ecstasy is most commonly ingested in tablet form; however,
the actual composition of tablets varies greatly. An
examination of tablets sold as ecstasy in Europe between
1995 and 1997 reveals that of 69 tablets, 30 contained MDMA,
with doses ranging from 2mg to 149mg and another eight
contained a mixture of substances including amphetamines,
ephedrine, caffeine and aspirin. Overall, approximately 10%
of drugs sold as ecstasy contain no active ingredient.
A more recent study conducted in the UK reported that
concentrations of MDMA varied 70-fold between tablets. This
is an important confounding factor for research into the effects
of ecstasy use.
The total amount consumed per occasion varies greatly
among users. The most common dosage is one to two tablets
per night, but case reports have indicated doses as high as 10
tablets. Tolerance to the psychoactive properties of MDMA
develops rapidly; therefore some individuals use increasing
amounts of ecstasy to reinforce the psychoactive effects.
Pharmacology
Ecstasy is the popular name for 3,4-methylenedioxy-
methamphetamine (MDMA). As the name implies, MDMA is a
derivative of methamphetamine (known by such street names
as speed, crystal and meth) and its parent compound,
amphetamine. Its structure also resembles that of mescaline
giving it some hallucinogenic properties. MDMA is an indirect
monoaminergic agonist, stimulating the release and inhibiting
the reuptake of serotonin.
The psychostimulant properties of ecstasy are observed 20
to 60 minutes after ingestion and its effects last from two to
four hours. It is widely distributed, easily crosses the
blood/brain barrier, is hepatically metabolised by CYP2D6
and is renally excreted. The pharmacokinetics of MDMA are
nonlinear: a small increase in dosage leads to a
disproportionate rise in drug plasma concentration, thus
possibly explaining why some individuals develop acute toxic
reactions after apparently normal doses.6 Approximately 10%
of Caucasians are deficient in CYP2D6 and this may make
those individuals more susceptible to adverse reactions.
Effects of ecstasy
Single doses of MDMA have been administered to volunteers
in double-blind, placebo-controlled trials, although most
findings of the effects of ecstasy are based on recreational
MDMA users. The desired effects for which MDMA is used are
a feeling of euphoria and postponement of fatigue, sharpened
sensory perception, greater sociability and a heightened
sense of closeness to other people.
Due to the fact that MDMA causes increased arousal and
alertness, it is usually accompanied by adverse effects such
as trismus, bruxism and restlessness. Homeostatic control of
body temperature is adversely affected due to altered
hypothalamic control, leading to an increase in body
temperature, sweating and dehydration.7 This has led to
reports of death due to hyperthermia, hyponatraemia due to
water intoxication, the syndrome of inappropriate antidiuretic
hormone (SIADH) and disseminated intravascular
coagulation (DIC).1
Serotonin syndrome
Ecstasy may induce the serotonin syndrome which is caused
by a drug-induced excess of intrasynaptic 5-
hydroxytryptamine (5-HT). The symptoms include
behavioural hyperactivity, mental confusion, agitation, hyper-
reflexia, hyperpyrexia, tachycardia, shivering, clonus,
myoclonus and tremor; it can be fatal.
It is difficult to estimate the morbidity of these reactions, which
raises the question of which factors influence the development
of serotonergic overactivity. One crucial factor is dosage, while
others include individual sensitivity, variations in drug
metabolism, tolerance, environmental factors and the
concomitant use of other psychoactive drugs which affect 5-HT.8
Long-term effects
The long-term serotonergic damage caused by MDMA was
first demonstrated in laboratory animals in the mid-1980s.
When rats were treated with successive doses of MDMA, they
developed a pronounced loss of 5-HT axon terminal
markers.9,10 Serotonergic changes have been shown in a
variety of indices, with dose-dependent reductions in 5-HT, 5-
hydroxyindole acetic acid (5-HIAA), tryptophan hydroxylase
and 5-HT uptake sites or neuronal transporters.
There are numerous indications of serotonergic damage in
humans. In a positron emission tomography (PET) scan study,
McCann et al (1998) documented a reduced density of 5-HT
transporter sites, which correlated with the extent of past
ecstasy use.11 These serotonergic deficits were found across a
wide range of brain regions. Significantly lower levels of
cerebrospinal fluid (CSF) serotonin and its metabolites have
also been found in abstinent ecstasy users.12 This evidence
would suggest that repeated ingestion of MDMA may
produce long-term reductions in serotonergic activity and
degeneration of serotonergic terminals in humans.
Psychiatric changes
Acute psychiatric effects from MDMA occur and include
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mood alteration and visual hallucinations. Chronic use may
lead to longer-term adverse psychiatric effects such as major
depression, panic disorder, psychosis and aggression.13,14
In a study, Parrott et al (2000) assessed 50 young adults in
an Irish town where drug use was prevalent. On the standard
psychiatric self-rating questionnaire (SCL-90), heavy ecstasy
users reported significantly higher scores than nonusers on
the following factors: general anxiety, phobic anxiety, hostility,
obsessionality, paranoid ideation, psychoticism, somatisation,
altered appetite, restless sleep and impulsiveness.
Concentration difficulties, memory disturbance and other
cognitive impairments have been demonstrated by many
different research studies, which would suggest a reason for
clinical concern.15
Conclusion
Ecstasy consumption is of growing concern, especially in the
young population and is, at present, second only to cannabis
use in this population in a number of European countries
including Ireland. One area of concern was outlined in a
study carried out in Dublin by Gervin et al (2000) where the
authors found an association between heroin smoking by
‘chasing the dragon’ to ‘come down’ off the effects of ecstasy.
One-quarter of the study’s sample population cited this as
their main reason for commencing opiates.16
There is a considerable body of evidence that ecstasy use
not only may have acute adverse effects but repeated use
may also have serious long-term consequences. Although
subtle at first, its effects may develop into major
neuropsychiatric syndromes over the lifetime of an otherwise
healthy individual. Even if these long-term effects are
confined to a small proportion of susceptible individuals, the
negative consequences of MDMA exposure could develop
into a major public health problem given the large number of
young people who use it. In order to prevent this, it is
important that comprehensive educational programmes are
developed to educate this young population about the many
long-term adverse effects of taking ecstasy.
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